ARAY logo

ACCURAY INC

ARAYNASDAQ
πŸ† #4544 by market capUS Equity
$243.08β–Ό $12.88 (βˆ’5.30%)
Simulated price
πŸ””
Track ARAY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.3%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$41M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-12.3%
Declining
πŸ“ŠGross Margin
27.7%
Moderate
πŸ’΅FCF Margin
-3.5%
Thin
βš–οΈP/S Ratio
0.1x
Cheap
Otter Score
60
Fair
No chart data available for ARAY.

Trading Snapshot

Day Range
$239.82 – $245.70
52-Week Range
$0.22 – $2.10
Volume
$3.12B
Avg Volume
$2.65B
Shares Outstanding
119.0M
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$402M
Last Q Revenue
$101M
P/E Ratio
-0.9
P/S Ratio
0.1x
EPS (TTM)
$-0.40
Dividend Yield
0.00%
Dilution (1yr)
+2.2%

Why Investors Own ARAY

  • βœ“High-growth profile β€” revenue up +11.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 77% gross margin and 27% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ARAY logo

ACCURAY INC

ARAY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$402Mβ–Ό βˆ’12.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
27.7%β–Ό βˆ’13.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$26Mβ–Ό βˆ’437.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$13Mβ–² +126.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
122.6Mβ–² +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$143Mβ–² +$20M YoY
StockOtter Β· stockotter.space

About ACCURAY INC

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$321.03
β–² +32.1% Upside
High Target$365.44
Low Target$265.77
Based on 31 analysts

Latest News & Updates